<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Thyroid function in nonthyroidal illness</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Thyroid function in nonthyroidal illness</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Thyroid function in nonthyroidal illness</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Assessment of thyroid function in patients with nonthyroidal illness is difficult, especially among those hospitalized in an intensive care unit (ICU). Many of them have low serum concentrations of both thyroxine (T4) and triiodothyronine (T3), and their serum thyroid-stimulating hormone (TSH) concentration also may be low. Previously, these patients were thought to be euthyroid, and the term euthyroid-sick syndrome was used to describe the laboratory abnormalities. However, there is evidence that some of these patients may have acquired transient central hypothyroidism [<a href="#rid1">1,2</a>]. It is possible that the early changes in thyroid function (low T3 and elevated reverse [rT3]) during severe illness are <strong>protective</strong> in that they prevent excessive tissue catabolism [<a href="#rid3">3</a>]. On the other hand, the subsequent alterations in thyroid hormone levels may be maladaptive, depending on the clinical circumstances [<a href="#rid4">4</a>].</p><p>This topic will review the changes in thyroid hormone and TSH production and metabolism that can occur in patients with nonthyroidal illness. The utility of the different tests to assess thyroid function is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function"</a>.)</p><p class="headingAnchor" id="H2910876247"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>Important general principles are as follows [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid function should not be assessed in seriously ill patients unless there is a strong suspicion of thyroid dysfunction, since there are many other factors in acutely or chronically ill euthyroid patients that influence thyroid function tests.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In hospitalized or ill patients in whom TSH measurement is necessary (eg, a sick patient with paroxysmal atrial fibrillation), TSH assays that have a detection limit of 0.01 mU/L should be used to assess thyroid function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When thyroid dysfunction is suspected in critically ill patients, measurement of serum TSH alone is inadequate for the evaluation of thyroid function. In such a patient, TSH and free T4 (and often total T3) are needed to differentiate nonthyroidal illness from a thyroid disorder. However, the diagnosis may still be in doubt.</p><p></p><p class="headingAnchor" id="H50200146"><span class="h1">CHANGES IN THYROID HORMONE TESTS</span><span class="headingEndMark"> — </span>Many hospitalized/ill patients have patterns of thyroid function that are similar to patients with central hypothyroidism: low or low-normal serum total T4, low T3 concentrations, and low, low-normal, or normal TSH [<a href="#rid6">6</a>]. It is possible that these changes in thyroid function during severe illness are protective in that they prevent excessive tissue catabolism [<a href="#rid1">1,3,4</a>].</p><p class="headingAnchor" id="H987519111"><span class="h2">TSH</span><span class="headingEndMark"> — </span>Euthyroid patients with nonthyroidal illness, especially those receiving high-dose glucocorticoids (&gt;20 mg/day <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or its equivalent), dopamine, or <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a> may have low serum TSH  (<a class="graphic graphic_figure graphicRef61095" href="/z/d/graphic/61095.html" rel="external">figure 1</a>), although it would be unusual for the TSH to be undetectable in an assay with a detection limit of 0.01 mU/L in the absence of thyrotoxicosis. If a more sensitive TSH assay (detection limit of 0.01 mU/L) is used, the serum TSH values in patients being given these drugs are usually in the range of 0.08 to 0.4 mU/L. These values can easily be distinguished from the suppressed values in patients with hyperthyroidism (&lt;0.01 mU/L). (See <a class="local">'TSH subnormal'</a> below and <a class="local">'Drugs'</a> below.)</p><p>In addition, cytokines and inflammation lower TSH levels, possibly by reducing hypothalamic thyrotropin-releasing hormone (TRH) production [<a href="#rid4">4,7</a>]. Patients with nonthyroidal illness, similar to those with central hypothyroidism from other causes, have a blunted nocturnal rise in serum TSH concentrations but usually have a normal serum TSH response to TRH [<a href="#rid8">8</a>]. Abnormalities in TSH glycosylation that may decrease TSH bioactivity have been found in patients with nonthyroidal illness [<a href="#rid9">9</a>] and also in patients with central hypothyroidism [<a href="#rid10">10</a>]. (See <a class="local">'Acquired transient central hypothyroidism'</a> below.)</p><p>Some hospitalized patients have transient elevations in serum TSH concentrations (up to 20 mU/L) during recovery from severe nonthyroidal illness. (See <a class="local">'TSH high'</a> below.)</p><p class="headingAnchor" id="H3698726764"><span class="h2">Serum total and free T4</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total T4</strong> – From 15 to 20 percent of hospitalized patients and up to 50 percent of patients in intensive care units (ICUs) have low serum T4 concentrations (low T4 syndrome)  (<a class="graphic graphic_figure graphicRef61095" href="/z/d/graphic/61095.html" rel="external">figure 1</a>). The concentrations are low because of reductions in the serum concentrations of one or more of the three thyroid hormone-binding proteins: thyroxine-binding globulin (TBG), transthyretin (TTR, or thyroxine-binding prealbumin [TBPA]), and albumin.</p><p></p><p class="bulletIndent1">Since TBG is the major binding protein, low serum T4 values are likely the result of decreased production of normal TBG or production of TBG that binds T4 poorly because it is abnormally glycosylated or is cleaved in the circulation [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Free T4</strong> – Free T4 levels may be normal, increased, or decreased. All methods for assessing free T4 levels are unreliable in severe critical illness, including free T4 by mass spectrometry [<a href="#rid12">12</a>]; a free T4 by equilibrium dialysis sent to a reference laboratory would be the least likely to provide spurious results. Some experts argue a total T4 is more informative than free T4 measurements in critical illness [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">Small reductions in binding proteins should not alter serum free T4 index or direct free T4 values, and these values are usually normal in patients whose illness is not severe. However, when the concentrations of binding proteins are very low, the T3 uptake test (and therefore the calculated thyroid hormone-binding ratio) fails to correct for the binding-protein deficiency adequately and the serum free T4 index is low  (<a class="graphic graphic_figure graphicRef61095" href="/z/d/graphic/61095.html" rel="external">figure 1</a>) [<a href="#rid14">14</a>]. The effects of nonthyroidal illness and drugs on "direct" free T4 measurements may be method dependent and also result in low values (or occasionally spuriously high values). (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Serum free T4 and T3'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibitors of T4 binding</strong> – An additional problem occurs in patients with more severe critical illness because some of them have circulating substances that inhibit T4 binding to the binding proteins. The result is a further reduction in serum total T4 concentrations and, frequently, low serum free T4 concentrations [<a href="#rid15">15</a>] and low serum free T4 index values. However, the serum free T4 fraction measured by equilibrium dialysis may be normal or even slightly high in these patients [<a href="#rid16">16</a>]. In one study, as an example, none of 25 patients with nonthyroidal illness had a low serum concentration of free T4 by equilibrium dialysis [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">Controversy exists as to the cause and importance of inhibitors of T4 binding to its binding proteins in patients with nonthyroidal illness [<a href="#rid16">16</a>]. Some data support the possibility that high serum free fatty acid concentrations inhibit T4 binding to serum proteins [<a href="#rid18">18,19</a>]. Serum free fatty acid, particularly oleic acid, concentrations may be high in critically ill patients [<a href="#rid20">20</a>], and their effect on T4 binding may be increased due to hypoalbuminemia because albumin is the major carrier of free fatty acids in serum [<a href="#rid21">21</a>]. However, this phenomenon may be an in vitro effect of fatty acids released during collection and transport of the serum sample [<a href="#rid22">22</a>]. Inhibitors may also interfere with the T3-resin uptake test by interacting with the solid matrices used in the test [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H2"><span class="h2">Low serum T3</span><span class="headingEndMark"> — </span>The majority of hospitalized patients have low serum T3 concentrations, as do some outpatients who are ill  (<a class="graphic graphic_figure graphicRef61095" href="/z/d/graphic/61095.html" rel="external">figure 1</a>). Unlike T4, which is produced solely within the thyroid, 80 percent of circulating T3 is produced by the peripheral 5'-deiodination of T4 to T3, a reaction catalyzed by 5'-monodeiodinases (D1 and D2) in organs such as muscle, liver, and kidney  (<a class="graphic graphic_figure graphicRef57919" href="/z/d/graphic/57919.html" rel="external">figure 2</a>). 5'-monodeiodination decreases whenever caloric intake is low and in any nonthyroidal illness, even when mild [<a href="#rid24">24</a>]. Liver and skeletal muscle biopsies obtained within minutes after death from ICU patients demonstrate reduced 5'-monodeiodinase activity and increased 5-monodeiodinase (D3) activity (which converts T4 to reverse T3 [rT3]) [<a href="#rid25">25,26</a>]. Patients with fatal illness have low tissue T4 and T3 concentrations [<a href="#rid27">27,28</a>].</p><p>Several mechanisms can contribute to the inhibition of 5'-monodeiodination and therefore to the low serum T3 concentrations in patients with nonthyroidal illness. They are:</p><p class="bulletIndent1"><span class="glyph">●</span>High endogenous serum cortisol concentrations and exogenous glucocorticoid therapy [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Circulating inhibitors of deiodinase activity, such as free (nonesterified) fatty acids [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with drugs that inhibit 5'-monodeiodinase activity, such as <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> and high doses of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cytokines (such as tumor necrosis factor, interferon alpha, nuclear factor kappa-B [NF-kB], and interleukin-6) [<a href="#rid7">7,31-33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum samples from patients with nonthyroidal illness impair uptake of T4 into cultured rat hepatocytes, thereby reducing the availability of substrate for conversion to T3 [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">High reverse T3</span><span class="headingEndMark"> — </span>Serum rT3 concentrations are high in patients with nonthyroidal illnesses  (<a class="graphic graphic_figure graphicRef61095" href="/z/d/graphic/61095.html" rel="external">figure 1</a>), except in those with renal failure [<a href="#rid35">35,36</a>] and in some with acquired immune deficiency syndrome (AIDS) [<a href="#rid37">37,38</a>]. rT3 is the product of 5-monodeiodination of T4 (D3)  (<a class="graphic graphic_figure graphicRef57919" href="/z/d/graphic/57919.html" rel="external">figure 2</a>); D3 is induced in nonthyroidal illness, especially in the setting of hypoxia or ischemia [<a href="#rid25">25,39</a>]. The clearance of rT3 to diiodothyronine (T2) is reduced in nonthyroidal illness because of inhibition of the 5'-monodeiodinase activity [<a href="#rid40">40</a>]. As a result, serum levels of rT3 are elevated. (See  <a class="medical medical_review" href="/z/d/html/7837.html" rel="external">"Thyroid hormone synthesis and physiology"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Acquired transient central hypothyroidism</span><span class="headingEndMark"> — </span>Patients with severe nonthyroidal illness may have acquired transient central hypothyroidism [<a href="#rid1">1</a>]. This suggestion is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study evaluated changes in thyroid function in patients undergoing bone marrow transplantation; serum TSH concentrations fell coincident with declines in serum T4 concentrations [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of critically ill patients recovering from nonthyroidal illness demonstrated that a rise in serum TSH concentration (which transiently reached supranormal values in some patients) <strong>preceded</strong> normalization of serum T4 concentrations [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with nonthyroidal illness, similar to those with central hypothyroidism from other causes, have a blunted nocturnal rise in serum TSH concentrations but usually have a normal serum TSH response to TRH [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in TSH glycosylation that may decrease TSH bioactivity have been found in patients with nonthyroidal illness [<a href="#rid9">9</a>] and also in patients with central hypothyroidism [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TRH mRNA in the paraventricular nucleus of the hypothalamus was reduced in patients who died with nonthyroidal illness in one report and was correlated with premortem serum T3 and TSH concentrations [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TRH (protirelin) infusion in patients with critical illness raises serum TSH, T4, and T3 concentrations [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infusion of interferon alfa to eight normal men caused a fall in serum TSH and T3 concentrations as well as a rise in the serum concentrations of rT3 and interleukin-6, thus mimicking the thyroid metabolic changes of serious illness, except that there was no fall in the serum T4 concentration [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Animal studies support the hypothesis that inflammation (eg, injection of endotoxin in rodents) upregulates hypothalamic deiodinase D2, which increases local T3 production and lowers TRH mRNA expression [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H838434413"><span class="h1">DRUGS AND DISORDERS ASSOCIATED WITH NONTHYROIDAL ILLNESS</span></p><p class="headingAnchor" id="H14"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Hospitalized patients frequently receive medications that have important effects on thyroid function or on thyroid function tests  (<a class="graphic graphic_table graphicRef50439" href="/z/d/graphic/50439.html" rel="external">table 1</a>). Dopamine, <a class="drug drug_general" data-topicid="9380" href="/z/d/drug information/9380.html" rel="external">dobutamine</a>, glucocorticoids, <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a>, nonsteroidal anti-inflammatory drugs (NSAIDs), heparin, anticonvulsants, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>, and drugs that affect thyroxine-binding globulin (TBG) can alter thyroid function tests in multiple complex ways that are often incompletely understood. (See  <a class="medical medical_review" href="/z/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones"</a> and  <a class="medical medical_review" href="/z/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Disorders</span><span class="headingEndMark"> — </span>Several disease states are associated with abnormal thyroid function tests including acute hepatitis, hepatoma, acute intermittent porphyria, acromegaly, nephrotic syndrome, Cushing syndrome, acute psychosis, and depression. (See  <a class="medical medical_review" href="/z/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia"</a> and  <a class="medical medical_review" href="/z/d/html/3104.html" rel="external">"Endocrine dysfunction in the nephrotic syndrome"</a>.)</p><p>Some patients with acute psychiatric illnesses, particularly schizophrenia, have transient elevations in serum T4 concentrations with or without low serum TSH concentrations [<a href="#rid45">45-47</a>]. Patients with severe depression may have changes similar to those of patients with glucocorticoid excess. (See  <a class="medical medical_review" href="/z/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia"</a>.)</p><p class="headingAnchor" id="H3276577547"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3830922317"><span class="h2">Biochemical tests</span><span class="headingEndMark"> — </span>It is important to recognize nonthyroidal illness and to try to differentiate it from an underlying primary thyroid disorder, although the diagnosis may remain in doubt.</p><p>We suggest initial measurement of TSH and free T4. Some clinicians also measure total T3 and total T4 at the time of the initial testing to expedite decision making. Measurement of TSH alone can be misleading since a premorbid normal TSH is usually suppressed to subnormal values and a premorbid elevated TSH can rarely be suppressed to normal values. Serum TSH assays that have a detection limit of 0.01 mU/L should be used in assessing thyroid function in critically ill patients [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H1789014448"><span class="h3">TSH subnormal</span><span class="headingEndMark"> — </span>Almost all patients who have a subnormal but detectable serum TSH concentration (greater than 0.05 mU/L and less than 0.3 mU/L) will be euthyroid when reassessed after recovery from their illness. In contrast, approximately 75 percent of patients whose TSH is undetectable (&lt;0.01 mU/L) have thyrotoxicosis.</p><p class="bulletIndent1"><span class="glyph">●</span>In patients without a strong clinical suspicion of thyroid disease and minor TSH abnormalities (TSH between 0.05 and 0.3 mU/L with normal or low free T4), we reassess thyroid tests (TSH, free T4) after recovery.</p><p></p><p class="bulletIndent1">If true central hypothyroidism due to hypothalamic or pituitary disease remains in the differential diagnosis, measurement of serum cortisol can be helpful as it would be elevated in critical illness and low (or inappropriately normal) in patients with true central hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p></p><p class="bulletIndent1">Measurement of serum rT3 is only rarely useful in hospitalized patients to distinguish between nonthyroidal illness (high values) and central hypothyroidism (low values); the values are low in the latter patients because of low production of the substrate (T4) for rT3. In patients with mild hypothyroidism, however, serum rT3 concentrations may be normal or even slightly high [<a href="#rid49">49</a>], limiting its usefulness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with suspected hyperthyroidism (as an example, in a sick patient with paroxysmal atrial fibrillation) and TSH &lt;0.05 mU/L with elevated or high normal free T4, we measure total T3 (and sometimes total T4) to help distinguish between hyperthyroidism and nonthyroidal illness.</p><p></p><p class="bulletIndent1">The serum T3 value should be high (or high normal) in hyperthyroidism, but low (or low normal) in nonthyroidal illness. Rarely, a very sick patient with hyperthyroidism will have a low serum T3 concentration. In critically ill patients with suspected hyperthyroidism (TSH usually &lt;0.01 but can be as high as 0.05 mU/L, and normal or high normal serum T4 and/or T3), we suggest antithyroid drug therapy (thionamides), with a plan for reassessment after recovery from the nonthyroidal illness. (See  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Critically ill hyperthyroid patients'</a> and  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Initiation of therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2037307247"><span class="h3">TSH high</span><span class="headingEndMark"> — </span>As noted above, some hospitalized patients have transient elevations in serum TSH concentrations (up to 20 mU/L) during recovery from nonthyroidal illness [<a href="#rid48">48</a>]. Few of these patients prove to have hypothyroidism when reevaluated after full recovery from their illness. Patients with serum TSH concentrations over 20 mU/L usually have permanent hypothyroidism [<a href="#rid50">50</a>]. Our approach depends on the degree of TSH elevation and the clinical suspicion for underlying hypothyroidism:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TSH between upper limit of normal and &lt;10 mU/L</strong> – If the patient appears to be recovering from the underlying illness, we <strong>repeat</strong> the TSH in one to two weeks. Few of these patients prove to have hypothyroidism when reevaluated after recovery from their illness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TSH 10 to 20 mU/L</strong> – Treatment with <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> may be appropriate depending on the free T4 level, clinical suspicion of hypothyroidism, and degree of nonthyroidal illness. (See  <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1">If uncertain, repeat the TSH and free T4 in one to two weeks. Thyroid function tests may improve in patients recovering from nonthyroidal illness.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TSH ≥20 mU/L</strong> – Assess the free T4 level.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Free T4 low</strong> – Hypothyroidism is likely. Initiate thyroid hormone. In the absence of suspected myxedema coma, repletion should be cautious, beginning with approximately half the expected full replacement dose of T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>). In suspected myxedema coma, or in critically ill patients who cannot ingest or absorb oral medications, thyroid hormone should be given intravenously. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Standard replacement therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7822.html" rel="external">"Myxedema coma", section on 'Thyroid hormone'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Free T4 normal</strong> – Repeat TSH and free T4 in one to two weeks. Thyroid function tests may improve in patients recovering from nonthyroidal illness.</p><p></p><p class="headingAnchor" id="H1178850489"><span class="h3">TSH normal</span><span class="headingEndMark"> — </span>Most patients with normal TSH and low free T4 will be euthyroid when reassessed after recovery from their illness. Rarely, an elevated TSH in a sick hypothyroid patient will be suppressed into the normal range. We reassess thyroid tests (TSH, free T4) after recovery. If true central hypothyroidism due to hypothalamic or pituitary disease remains in the differential diagnosis, measurement of serum cortisol can be helpful as it would be elevated in critical illness and low (or inappropriately normal) in patients with true central hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p class="headingAnchor" id="H2165964593"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>In critically ill patients with low free T4 and total T3 who do not appear to have an underlying primary thyroid disorder, we recommend not treating with thyroid hormone. There is no evidence that thyroid hormone replacement is beneficial for patients with critical illness who have low serum T4 or T3 concentrations, or for patients undergoing coronary artery bypass graft surgery (CABG), whose serum T3 concentrations are known to decrease in the perioperative period [<a href="#rid3">3,6</a>]. In addition, during fasting, when there is an associated decrease in serum T3 concentrations that spares muscle protein, T3 (<a class="drug drug_general" data-topicid="9563" href="/z/d/drug information/9563.html" rel="external">liothyronine</a>) replacement results in increased catabolism with breakdown of skeletal muscle [<a href="#rid51">51,52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Critical illness</strong> – Thyroid hormone replacement does not appear to be beneficial for critically ill patients with low serum T3 and/or low T4 concentrations. In a randomized trial of burn patients with low free T4 index and free T3 index levels, T3 replacement had no effect on mortality or metabolic rate when compared with placebo [<a href="#rid53">53</a>]. In a second trial, administration of T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>) to 23 critically ill patients with low serum T4 concentrations did not alter either mortality or outcome [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac disease</strong> – During and after cardiopulmonary bypass, there is a transient decrease in serum T3 concentrations, which may contribute to postoperative hemodynamic problems [<a href="#rid52">52</a>]. While animal data and anecdotal clinical experience had suggested that T3 repletion might improve outcomes after cardiopulmonary bypass [<a href="#rid55">55,56</a>], clinical trials have not demonstrated such a benefit [<a href="#rid57">57-59</a>].</p><p></p><p class="bulletIndent1">In a systematic review of 14 randomized trials evaluating the administration of T3 in euthyroid adult patients in the immediate postoperative period (13 cardiac surgery, one renal transplantation), intravenous (IV) T3 administration increased cardiac index [<a href="#rid60">60</a>]. Mortality was not affected by high-dose IV T3 and could not be assessed for low-dose IV or oral T3. In one of the trials included in the meta-analysis, 142 patients with coronary heart disease undergoing CABG were randomly assigned to intravenous T3 therapy (0.8 mcg/kg bolus followed by an infusion of 0.113 mcg/kg/hour for six hours) at the completion of surgery or placebo [<a href="#rid57">57</a>]. Although the mean cardiac index was higher and systemic vascular resistance was lower in the T3 group compared with placebo, there were no differences in the incidence of arrhythmia, need for inotropic or vasodilator drugs during the 24 hours after surgery, or in perioperative morbidity and mortality. A subsequent randomized controlled trial using oral T3 (20 mcg every 12 hours) also failed to demonstrate a clinical benefit [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> is an antioxidant that prevents reductions in glutathione, a cofactor of the D1 deiodinase. In a randomized controlled trial of patients presenting with myocardial infarction, N-acetylcysteine ameliorated the fall in T3 and rise in reverse T3 (rT3) [<a href="#rid62">62</a>]. Whether this is beneficial or harmful has yet to be determined. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>In patients with ischemic heart disease, changes in thyroid tests consistent with nonthyroidal illness are associated with an increase in overall mortality (hazard ratio [HR] 2.61, 95% CI 1.89-3.59) and major adverse cardiac events (HR 2.22, 95% CI 1.71-2.89) [<a href="#rid63">63</a>]. In patients hospitalized with coronavirus disease 2019 (COVID-19), there was an increased risk of death, intensive care unit (ICU) admission, or need for ventilation in patients with severe nonthyroidal illness compared with those with normal thyroid function (HR 23, 95% CI 5.8-93) [<a href="#rid64">64</a>]. </p><p>The magnitude of the changes in thyroid function in patients with nonthyroidal illness varies with the severity of the illness  (<a class="graphic graphic_figure graphicRef61095" href="/z/d/graphic/61095.html" rel="external">figure 1</a>). Low serum T3 has been shown to correlate with increased hospital stay, ICU admission, and need for mechanical ventilation in patients with acute heart failure [<a href="#rid65">65</a>] and predicts 30-day mortality in patients with community-acquired pneumonia [<a href="#rid66">66</a>]. The serum T4 value also correlates with outcome in critically ill patients; values under 3 mcg/dL have been associated with mortality rates in excess of 85 percent [<a href="#rid67">67</a>].</p><p>However, there is some evidence that low serum T3 levels may be beneficial in critically ill patients. In a randomized trial of early versus late <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> in critically ill ICU patients, tolerating a nutritional deficit for one week was associated with fewer complications and faster recovery from organ failure [<a href="#rid68">68</a>]. The patients who tolerated the nutritional deficit for one week had lower TSH, T4, T3, and T3/reverse T3 (rT3) ratios [<a href="#rid69">69</a>]. Lower T3 but higher T4 was associated with a higher likelihood of early alive ICU discharge. These data suggest that inactivation of T4-to-T3 conversion during starvation and illness may be a beneficial adaptation, while very low T4 levels due to "acquired central hypothyroidism" in more critically ill patients are associated with deleterious outcomes [<a href="#rid69">69,70</a>]. Furthermore, in one study, administering 100 percent of estimated caloric needs in ventilated patients with systemic inflammatory response syndrome resulted in only a transient increase (54 percent increase on the first treatment day, but lost by the third day) in the T3/rT3 ratio compared with patients receiving 40 percent of caloric needs [<a href="#rid71">71</a>]. (See  <a class="medical medical_review" href="/z/d/html/7891.html" rel="external">"Laboratory assessment of thyroid function", section on 'Laboratory tests used to assess thyroid function'</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid function should not be assessed in seriously ill patients unless there is a strong suspicion of thyroid dysfunction, since there are many other factors in acutely or chronically ill euthyroid patients that influence thyroid function tests. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many hospitalized ill patients (especially those in an intensive care unit [ICU]) have low serum concentrations of total thyroxine (T4) and triiodothyronine (T3), and their serum thyroid-stimulating hormone (TSH) concentrations are typically low, but may be low-normal or normal. (See <a class="local">'Changes in thyroid hormone tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When thyroid dysfunction is suspected in critically ill patients, measurement of serum TSH alone is inadequate for the evaluation of thyroid function. We suggest initial measurement of TSH and free T4. Some clinicians also measure a total T3 and total T4 at the time of the initial testing to expedite decision making. However, the diagnosis may still be in doubt. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In critically ill patients without a strong clinical suspicion of thyroid disease and minor TSH abnormalities (eg, normal or low free T4 with TSH between 0.05 and 0.3 mU/L or TSH between the upper limit of normal and &lt;20 mU/L), we repeat thyroid tests (TSH, free T4), typically in one to two weeks. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In critically ill patients with suspected hyperthyroidism (TSH usually &lt;0.01 but can be as high as 0.05 mU/L, and normal or high-normal serum T4 and/or T3), we suggest antithyroid drug therapy (thionamides) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), with a plan for reassessment after recovery from the nonthyroidal illness. (See <a class="local">'TSH subnormal'</a> above and  <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Initiation of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Critically ill patients with suspected hypothyroidism and TSH ≥20 mU/L with low free T4 low should be treated with thyroid hormone replacement and reassessed after recovery. In the absence of suspected myxedema coma, repletion should be cautious, beginning with approximately half the expected full replacement dose of T4 (<a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>). (See <a class="local">'TSH high'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In critically ill patients with low free T4 and total T3 who do not appear to have an underlying primary thyroid disorder, we recommend not treating with thyroid hormone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In previously euthyroid patients undergoing coronary artery bypass graft (CABG), we recommend <strong>not</strong> treating with thyroid hormone in the immediate postoperative period (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Management'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chopra IJ. Clinical review 86: Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 1997; 82:329.</a></li><li><a class="nounderline abstract_t">Lee S, Farwell AP. Euthyroid Sick Syndrome. Compr Physiol 2016; 6:1071.</a></li><li><a class="nounderline abstract_t">Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med 1995; 333:1562.</a></li><li><a class="nounderline abstract_t">Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol 2015; 3:816.</a></li><li><a class="nounderline abstract_t">Stockigt JR. Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness. Clin Chem 1996; 42:188.</a></li><li><a class="nounderline abstract_t">Moura Neto A, Zantut-Wittmann DE. Abnormalities of Thyroid Hormone Metabolism during Systemic Illness: The Low T3 Syndrome in Different Clinical Settings. Int J Endocrinol 2016; 2016:2157583.</a></li><li><a class="nounderline abstract_t">Corssmit EP, Heyligenberg R, Endert E, et al. Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab 1995; 80:3140.</a></li><li><a class="nounderline abstract_t">Romijn JA, Wiersinga WM. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 1990; 70:35.</a></li><li><a class="nounderline abstract_t">Lee HY, Suhl J, Pekary AE, Hershman JM. Secretion of thyrotropin with reduced concanavalin-A-binding activity in patients with severe nonthyroid illness. J Clin Endocrinol Metab 1987; 65:942.</a></li><li><a class="nounderline abstract_t">Persani L, Ferretti E, Borgato S, et al. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000; 85:3631.</a></li><li><a class="nounderline abstract_t">Jirasakuldech B, Schussler GC, Yap MG, et al. A characteristic serpin cleavage product of thyroxine-binding globulin appears in sepsis sera. J Clin Endocrinol Metab 2000; 85:3996.</a></li><li><a class="nounderline abstract_t">Welsh KJ, Stolze BR, Yu X, et al. Assessment of thyroid function in intensive care unit patients by liquid chromatography tandem mass spectrometry methods. Clin Biochem 2017; 50:318.</a></li><li><a class="nounderline abstract_t">Stockigt J. Assessment of thyroid function: towards an integrated laboratory--clinical approach. Clin Biochem Rev 2003; 24:109.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Solomon DH, Hepner GW, Morgenstein AA. Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med 1979; 90:905.</a></li><li><a class="nounderline abstract_t">Wong TK, Pekary AE, Hoo GS, et al. Comparison of methods for measuring free thyroxin in nonthyroidal illness. Clin Chem 1992; 38:720.</a></li><li><a class="nounderline abstract_t">Docter R, Krenning EP, de Jong M, Hennemann G. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) 1993; 39:499.</a></li><li><a class="nounderline abstract_t">Chopra IJ. Simultaneous measurement of free thyroxine and free 3,5,3'-triiodothyronine in undiluted serum by direct equilibrium dialysis/radioimmunoassay: evidence that free triiodothyronine and free thyroxine are normal in many patients with the low triiodothyronine syndrome. Thyroid 1998; 8:249.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Teco GN, Mead JF, et al. Relationship between serum free fatty acids and thyroid hormone binding inhibitor in nonthyroid illnesses. J Clin Endocrinol Metab 1985; 60:980.</a></li><li><a class="nounderline abstract_t">Lim CF, Bernard BF, de Jong M, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993; 76:318.</a></li><li><a class="nounderline abstract_t">Lim CF, Curtis AJ, Barlow JW, et al. Interactions between oleic acid and drug competitors influence specific binding of thyroxine in serum. J Clin Endocrinol Metab 1991; 73:1106.</a></li><li><a class="nounderline abstract_t">Mendel CM, Frost PH, Cavalieri RR. Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin. J Clin Endocrinol Metab 1986; 63:1394.</a></li><li><a class="nounderline abstract_t">Faber J, Waetjen I, Siersbaek-Nielsen K. Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin. Clin Chim Acta 1993; 223:159.</a></li><li><a class="nounderline abstract_t">Oppenheimer JH, Schwartz HL, Mariash CN, Kaiser FE. Evidence for a factor in the sera of patients with nonthyroidal disease which inhibits iodothyronine binding by solid matrices, serum proteins, and rat hepatocytes. J Clin Endocrinol Metab 1982; 54:757.</a></li><li><a class="nounderline abstract_t">Davidson MB, Chopra IJ. Effect of carbohydrate and noncarbohydrate sources of calories on plasma 3,5,3'-triiodothyronine concentrations in man. J Clin Endocrinol Metab 1979; 48:577.</a></li><li><a class="nounderline abstract_t">Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003; 88:3202.</a></li><li><a class="nounderline abstract_t">Peeters RP, Wouters PJ, van Toor H, et al. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005; 90:4559.</a></li><li><a class="nounderline abstract_t">Peeters RP, Kester MH, Wouters PJ, et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab 2005; 90:6460.</a></li><li><a class="nounderline abstract_t">Arem R, Wiener GJ, Kaplan SG, et al. Reduced tissue thyroid hormone levels in fatal illness. Metabolism 1993; 42:1102.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41:911.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Huang TS, Beredo A, et al. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab 1985; 60:666.</a></li><li><a class="nounderline abstract_t">van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 1990; 71:1567.</a></li><li><a class="nounderline abstract_t">Stouthard JM, van der Poll T, Endert E, et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 1994; 79:1342.</a></li><li><a class="nounderline abstract_t">Nagaya T, Fujieda M, Otsuka G, et al. A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. J Clin Invest 2000; 106:393.</a></li><li><a class="nounderline abstract_t">Vos RA, De Jong M, Bernard BF, et al. Impaired thyroxine and 3,5,3'-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. J Clin Endocrinol Metab 1995; 80:2364.</a></li><li><a class="nounderline abstract_t">Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG. Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab 1983; 57:181.</a></li><li><a class="nounderline abstract_t">Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996; 17:45.</a></li><li><a class="nounderline abstract_t">LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:970.</a></li><li><a class="nounderline abstract_t">Ricart-Engel W, Fernández-Real JM, González-Huix F, et al. The relation between thyroid function and nutritional status in HIV-infected patients. Clin Endocrinol (Oxf) 1996; 44:53.</a></li><li><a class="nounderline abstract_t">Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab 2008; 4:148.</a></li><li><a class="nounderline abstract_t">Chopra IJ. An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man. J Clin Invest 1976; 58:32.</a></li><li><a class="nounderline abstract_t">Wehmann RE, Gregerman RI, Burns WH, et al. Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness. N Engl J Med 1985; 312:546.</a></li><li><a class="nounderline abstract_t">Hamblin PS, Dyer SA, Mohr VS, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab 1986; 62:717.</a></li><li><a class="nounderline abstract_t">Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 1997; 82:4032.</a></li><li><a class="nounderline abstract_t">Van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84:1311.</a></li><li><a class="nounderline abstract_t">Spratt DI, Pont A, Miller MB, et al. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73:41.</a></li><li><a class="nounderline abstract_t">Chopra IJ, Solomon DH, Huang TS. Serum thyrotropin in hospitalized psychiatric patients: evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay. Metabolism 1990; 39:538.</a></li><li><a class="nounderline abstract_t">Roca RP, Blackman MR, Ackerley MB, et al. Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism. Endocr Res 1990; 16:415.</a></li><li><a class="nounderline abstract_t">Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990; 70:453.</a></li><li><a class="nounderline abstract_t">Burmeister LA. Reverse T3 does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome. Thyroid 1995; 5:435.</a></li><li><a class="nounderline abstract_t">Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients: a systematic review. Arch Intern Med 1999; 159:658.</a></li><li><a class="nounderline abstract_t">Vignati L, Finley RJ, Hagg S, Aoki TT. Protein conservation during prolonged fast: a function of triiodothyronine levels. Trans Assoc Am Physicians 1978; 91:169.</a></li><li><a class="nounderline abstract_t">Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 1979; 300:579.</a></li><li><a class="nounderline abstract_t">Becker RA, Vaughan GM, Ziegler MG, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med 1982; 10:870.</a></li><li><a class="nounderline abstract_t">Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986; 63:1.</a></li><li><a class="nounderline abstract_t">Broderick TJ, Wechsler AS. Triiodothyronine in cardiac surgery. Thyroid 1997; 7:133.</a></li><li><a class="nounderline abstract_t">Novitzky D, Fontanet H, Snyder M, et al. Impact of triiodothyronine on the survival of high-risk patients undergoing open heart surgery. Cardiology 1996; 87:509.</a></li><li><a class="nounderline abstract_t">Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333:1522.</a></li><li><a class="nounderline abstract_t">Bennett-Guerrero E, Jimenez JL, White WD, et al. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery. A randomized, double-blind, placebo- controlled trial. Duke T3 study group. JAMA 1996; 275:687.</a></li><li><a class="nounderline abstract_t">Spratt DI, Frohnauer M, Cyr-Alves H, et al. Physiological effects of nonthyroidal illness syndrome in patients after cardiac surgery. Am J Physiol Endocrinol Metab 2007; 293:E310.</a></li><li><a class="nounderline abstract_t">Kaptein EM, Sanchez A, Beale E, Chan LS. Clinical review: Thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis. J Clin Endocrinol Metab 2010; 95:4526.</a></li><li><a class="nounderline abstract_t">Choi YS, Shim JK, Song JW, et al. Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2013; 27:1218.</a></li><li><a class="nounderline abstract_t">Vidart J, Wajner SM, Leite RS, et al. N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99:4537.</a></li><li><a class="nounderline abstract_t">Chang CY, Chien YJ, Lin PC, et al. Nonthyroidal Illness Syndrome and Hypothyroidism in Ischemic Heart Disease Population: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Zheng J, Cui Z, Shi N, et al. Suppression of the hypothalamic-pituitary-thyroid axis is associated with the severity of prognosis in hospitalized patients with COVID-19. BMC Endocr Disord 2021; 21:228.</a></li><li><a class="nounderline abstract_t">Rothberger GD, Gadhvi S, Michelakis N, et al. Usefulness of Serum Triiodothyronine (T3) to Predict Outcomes in Patients Hospitalized With Acute Heart Failure. Am J Cardiol 2017; 119:599.</a></li><li><a class="nounderline abstract_t">Liu J, Wu X, Lu F, et al. Low T3 syndrome is a strong predictor of poor outcomes in patients with community-acquired pneumonia. Sci Rep 2016; 6:22271.</a></li><li><a class="nounderline abstract_t">Slag MF, Morley JE, Elson MK, et al. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 1981; 245:43.</a></li><li><a class="nounderline abstract_t">Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506.</a></li><li><a class="nounderline abstract_t">Langouche L, Vander Perre S, Marques M, et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab 2013; 98:1006.</a></li><li><a class="nounderline abstract_t">Langouche L, Jacobs A, Van den Berghe G. Nonthyroidal Illness Syndrome Across the Ages. J Endocr Soc 2019; 3:2313.</a></li><li><a class="nounderline abstract_t">McKeever L, Peterson SJ, Lateef O, et al. Higher Caloric Exposure in Critically Ill Patients Transiently Accelerates Thyroid Hormone Activation. J Clin Endocrinol Metab 2020; 105.</a></li></ol></div><div id="topicVersionRevision">Topic 7817 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024211" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical review 86: Euthyroid sick syndrome: is it a misnomer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27065175" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Euthyroid Sick Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477174" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26071885" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyroid function in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565225" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27803712" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Abnormalities of Thyroid Hormone Metabolism during Systemic Illness: The Low T3 Syndrome in Different Clinical Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593416" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2104628" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Decreased nocturnal surge of thyrotropin in nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3667887" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Secretion of thyrotropin with reduced concanavalin-A-binding activity in patients with severe nonthyroid illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061514" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Circulating thyrotropin bioactivity in sporadic central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095421" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A characteristic serpin cleavage product of thyroxine-binding globulin appears in sepsis sera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890823" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Assessment of thyroid function in intensive care unit patients by liquid chromatography tandem mass spectrometry methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18568049" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Assessment of thyroid function: towards an integrated laboratory--clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/443685" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1582025" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of methods for measuring free thyroxin in nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252737" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9545112" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Simultaneous measurement of free thyroxine and free 3,5,3'-triiodothyronine in undiluted serum by direct equilibrium dialysis/radioimmunoassay: evidence that free triiodothyronine and free thyroxine are normal in many patients with the low triiodothyronine syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3920236" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Relationship between serum free fatty acids and thyroid hormone binding inhibitor in nonthyroid illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8432774" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1939526" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Interactions between oleic acid and drug competitors influence specific binding of thyroxine in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3782424" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143362" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Free thyroxine measured in undiluted serum by dialysis and ultrafiltration: effects of non-thyroidal illness, and an acute load of salicylate or heparin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7061687" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evidence for a factor in the sera of patients with nonthyroidal disease which inhibits iodothyronine binding by solid matrices, serum proteins, and rat hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/429502" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of carbohydrate and noncarbohydrate sources of calories on plasma 3,5,3'-triiodothyronine concentrations in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12843166" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886232" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189257" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412761" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Reduced tissue thyroid hormone levels in fatal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1242390" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2857729" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229314" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962327" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10930442" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629231" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impaired thyroxine and 3,5,3'-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6853675" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641223" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Thyroid hormone metabolism and thyroid diseases in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2567143" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8706293" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The relation between thyroid function and nutritional status in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18212764" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reawakened interest in type III iodothyronine deiodinase in critical illness and injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/932209" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881675" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3949952" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398708" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199772" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807087" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hyperthyroxinemia in patients with acute psychiatric disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2336036" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Serum thyrotropin in hospitalized psychiatric patients: evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2129342" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2105333" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Applications of a new chemiluminometric thyrotropin assay to subnormal measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8808092" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Reverse T3 does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218744" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis of thyroid disease in hospitalized patients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/382585" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Protein conservation during prolonged fast: a function of triiodothyronine levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/105290" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7140337" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hypermetabolic low triiodothyronine syndrome of burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3011834" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9086581" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Triiodothyronine in cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8904679" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Impact of triiodothyronine on the survival of high-risk patients undergoing open heart surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477166" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Thyroid hormone treatment after coronary-artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8594265" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery. A randomized, double-blind, placebo- controlled trial. Duke T3 study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426111" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Physiological effects of nonthyroidal illness syndrome in patients after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668034" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical review: Thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958074" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148231" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459357" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nonthyroidal Illness Syndrome and Hypothyroidism in Ischemic Heart Disease Population: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34781943" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Suppression of the hypothalamic-pituitary-thyroid axis is associated with the severity of prognosis in hospitalized patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28017303" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Usefulness of Serum Triiodothyronine (T3) to Predict Outcomes in Patients Hospitalized With Acute Heart Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26928863" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Low T3 syndrome is a strong predictor of poor outcomes in patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7431627" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypothyroxinemia in critically ill patients as a predictor of high mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714640" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Early versus late parenteral nutrition in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348400" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31745528" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nonthyroidal Illness Syndrome Across the Ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31581295" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Higher Caloric Exposure in Critically Ill Patients Transiently Accelerates Thyroid Hormone Activation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
